GRAL GRAIL, Inc.

NASDAQ
$105.60

GRAIL, Inc. (GRAL) is expected to report earnings on February 3, 2027, after the market close. The consensus earnings estimate is a loss of $2.05 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -11.6% since its last earnings release on November 4, 2026.

GRAIL Beat Consensus Estimates
Wednesday, November 4, 2026 · 4:02 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 3
Wednesday · 4:00 PM ET
Earnings Whisper
-
vs ($2.05)
Rev est $49.68M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $119.97

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About GRAIL, Inc.

GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured.

Sector

Healthcare

Industry

Medical Labs & Research

Charts powered in part by Lightweight Charts™ by TradingView.